<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11066">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962895</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736A2201</org_study_id>
    <nct_id>NCT02962895</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)</brief_title>
  <official_title>Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will determine the dose-response relationship of VAY736 for key efficacy and
      safety parameters
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Dose response measured by change multi-dimensional disease activity as assessed by the physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Dose response measured by change in patient-reported disease activity measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in quality of life measure by PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary gland function</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in salivary gland function measure by flow rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of Adverse events and Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Primary Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>VAY736 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 low</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAY736 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 medium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAY736 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 high</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <description>VAY736</description>
    <arm_group_label>VAY736 dose 1</arm_group_label>
    <arm_group_label>VAY736 dose 2</arm_group_label>
    <arm_group_label>VAY736 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfilled revised European US consensus criteria for pSS

          -  Seropositive at screening for anti-Ro/SSA antibodies

          -  Documented salivary/lacrimal gland biopsy result confirming pSS diagnosis prior to
             the baseline visit

        Exclusion Criteria:

          -  Secondary Sjogren's syndrome

          -  Use of other investigational drugs

          -  Active viral, bacterial or other infections

          -  Positive hepatitis B, hepatitis C, HIV or tuberculosis test results at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 9, 2016</lastchanged_date>
  <firstreceived_date>November 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
